Loma Linda University School of Public Health (LLUSPH) has been awarded a Global Research Award for Nicotine Dependence (GRAND). GRAND is an independently-reviewed competitive grants program supported by Pfizer to fund research into the treatment of tobacco and nicotine dependence.
[Photo: Dr. Pramil Singh]
The LLUH award will fund a landmark intervention study of over 700 smokers in Mongolia entitled “Comparative Effectiveness of Cytisine versus Nicotine Replacement Therapy in the National Smoking Cessation Program of Mongolia: A Pragmatic Non-Inferiority Trial”.
Cytisine is a naturally occurring alkaloid found in plants, specifically in members of the Leguminosae family. Cytisine provides a low-cost pharmacotherapy treatment for smoking cessation. The treatment will be tested in addiction clinics of the national health care system of Mongolia that target low to middle income adults.
Dr. Pramil Singh, of the Center for Health Research will serve as the principal investigator for the study. For the past 15 years, Dr. Singh has been working on tobacco-related research and capacity building projects in the US and Asia under funding from the NIH, WHO, Gates Foundation, and ASPPH.
Dr. Singh will lead a team of investigators from the United States, Poland, and Mongolia. The international team includes:
The two-year trial will begin to enroll subjects in the Fall of 2017.